Особенности течения ревматических заболеваний на фоне новой коронавирусной инфекции

V.V Vakhlevskiy,V.V Tyrenko,E.V Kryukov,I.S Svintsitskaya

doi:10.32364/2587-6821-2021-5-2-84-88

Abstract

The article describes the main pathophysiological mechanisms underlying the potential use of antirheumatic therapy in the new COVID-19 in patients with rheumatic diseases. Also, it summarizes current data on the risk and outcome of COVID-19 in patients with systemic autoimmune diseases. To date, there are no large randomized studies on the use of antirheumatic drugs in patients with rheumatic diseases in the setting of COVID-19. Besides, there is no convincing evidence that any disease-modifying antirheumatic drug (conventional synthetic, biological, or targeted synthetic) can prevent the development of a severe COVID-19 course. At the same time, the importance of concomitant pathology (hypertension, obesity, cardiovascular diseases, diabetes mellitus) and risk factors (smoking) in the development of a severe COVID-19 course in patients with rheumatic diseases is shown. The article presents possible options for initiating and continuing treatment with antirheumatic drugs in patients with rheumatic diseases, depending on the stage of the infectious disease process. KEYWORDS: COVID-19, rheumatic diseases, disease-modifying antirheumatic drug, interleukin, tumor necrosis factor, glucocorticosteroids. FOR CITATION: Vakhlevskiy V.V., Tyrenko V.V., Svintsitskaya I.S., Kryukov E.V. Patterns of the rheumatic disease course in the setting of a new coronavirus infection. Russian Medical Inquiry. 2021;5(2):84–88. DOI: 10.32364/2587-6821-2021-5-2-84-88.

Highlights

The article describes the main pathophysiological mechanisms underlying the potential use of antirheumatic therapy in the new COVID-19 in patients with rheumatic diseases
There is no convincing evidence that any disease-modifying antirheumatic drug can prevent the development of a severe COVID-19 course
Ревматические заболевания занимают значитель ное место в структуре общей заболеваемости населения во всех странах мира, в т. ч. и в России

Summary

Introduction

The article describes the main pathophysiological mechanisms underlying the potential use of antirheumatic therapy in the new COVID-19 in patients with rheumatic diseases. Пандемия коронавирусной инфекции COVID-19 (coronavirus disease 2019, прежнее название — 2019-nCoV), вызванная вирусом SARS-CoV-2, началась в декабре 2019 г. «Цитокиновый шторм» вызывает развитие острого ре спираторного дистресс-синдрома и полиорганной недоста точности при тяжелом течении SARS-CoV-2-инфекции, что приводит к летальному исходу [10,11,12].

Results

Conclusion